Tirzepatide vs Retatrutide: Dual vs Triple Agonist (2026)

Q: What is the difference between tirzepatide and retatrutide?

Tirzepatide is a dual GLP-1/GIP receptor agonist (sold as Mounjaro/Zepbound), while retatrutide is a triple GLP-1/GIP/glucagon receptor agonist still in Phase 3 trials. Retatrutide adds glucagon receptor activation, which may enhance fat burning and energy expenditure beyond what tirzepatide achieves.

Q: How much weight can you lose on retatrutide vs tirzepatide?

In clinical trials, tirzepatide (SURMOUNT-1) showed 22.5% mean weight loss at 72 weeks. Retatrutide (TRIUMPH-4 Phase 3) showed approximately 28.7% weight loss. However, retatrutide is not yet FDA-approved and these results are from different trial populations.

Q: What does the glucagon receptor do in retatrutide?

The glucagon receptor activation in retatrutide increases energy expenditure, promotes hepatic fat oxidation (liver fat burning), and may enhance thermogenesis. This third mechanism is what differentiates retatrutide from tirzepatide's dual GLP-1/GIP action and likely contributes to the greater weight loss observed in trials.

Q: Will retatrutide replace tirzepatide?

It's too early to say. Retatrutide shows greater weight loss in trials, but tirzepatide has an established safety record, FDA approval, and widespread availability. Both are made by Eli Lilly. Retatrutide may become a preferred option for patients needing maximum weight loss, while tirzepatide remains the proven standard.

Q: What are the side effects of retatrutide compared to tirzepatide?

Both share GI side effects (nausea, diarrhea, vomiting) common to GLP-1 agonists. Retatrutide's glucagon component may cause slightly elevated heart rate in some patients. Full Phase 3 safety data for retatrutide is still being collected. Tirzepatide has a more established and well-characterized safety profile.

💊 Tirzepatide

Brand Names
Mounjaro, Zepbound
Mechanism
Dual GLP-1/GIP agonist
Max Weight Loss
22.5% (SURMOUNT-1)
FDA Status
✅ Approved (T2D 2022, Obesity 2023)
Manufacturer
Eli Lilly
Key Trial
SURMOUNT program (N=2,539)
Dosing
Weekly injection, 2.5–15 mg
Cost
$1,000–$1,200/mo (cash)

🧪 Retatrutide

Brand Names
LY3437943 (investigational)
Mechanism
Triple GLP-1/GIP/Glucagon agonist
Max Weight Loss
28.7% (TRIUMPH-4 Phase 3)
FDA Status
❌ Not approved (Phase 3)
Manufacturer
Eli Lilly
Key Trial
TRIUMPH program
Dosing
Weekly injection (dose TBD)
Cost
Not yet available commercially

Mechanism of Action

Tirzepatide — The Dual Agonist

Tirzepatide activates two receptors simultaneously:

GLP-1 receptor: Reduces appetite, slows gastric emptying, enhances insulin secretion
GIP receptor: Improves insulin sensitivity, enhances fat metabolism in adipose tissue

Retatrutide — The Triple Agonist

Retatrutide adds a third target to the dual-agonist approach:

GLP-1 receptor: Same appetite and insulin benefits as tirzepatide
GIP receptor: Same metabolic and insulin sensitivity benefits
Glucagon receptor: Increases energy expenditure, promotes hepatic fat oxidation, enhances thermogenesis

💡 Why Does the Third Receptor Matter?

Think of it this way: tirzepatide reduces calorie intake (GLP-1) and improves how your body processes those calories (GIP). Retatrutide does both of those plus actively burns more calories through glucagon-mediated energy expenditure. It's the difference between eating less and eating less while your metabolism runs hotter.

Weight Loss Efficacy

Head-to-head comparison of maximum weight loss achieved in respective clinical trial programs:

Retatrutide (TRIUMPH-4)28.7%

28.7%

Tirzepatide 15mg (SURMOUNT-1)22.5%

22.5%

Semaglutide 2.4mg (STEP 1)14.9%

14.9%

Placebo + lifestyle~2.4%

2.4%

⚠️ Cross-Trial Comparison Caveat

These numbers come from separate clinical trials with different patient populations, inclusion criteria, and timeframes. Direct comparison requires a head-to-head trial, which has not been conducted between tirzepatide and retatrutide. The data is directionally informative but not statistically equivalent to a head-to-head comparison.

Side Effect Comparison

Both share the GI side effect profile common to GLP-1 agonists. Retatrutide's glucagon component introduces some unique considerations:

Nausea — Tirzepatide~26–33%

~33%

Nausea — Retatrutide~25–35%

~35%

Diarrhea — Tirzepatide~21–25%

~25%

Diarrhea — Retatrutide~22–28%

~28%

Elevated Heart Rate — Retatrutide~5–8%

~8%

⚖️ Who Should Choose What?

Tirzepatide is right for you if:

You want a proven, FDA-approved medication available now
You have type 2 diabetes (approved for both T2D and obesity)
Your insurance covers Mounjaro or Zepbound
You prefer a medication with an established multi-year safety record
You've plateaued on semaglutide and want to upgrade

Retatrutide may be worth watching if:

You want maximum possible weight loss (Phase 3 data is very promising)
You have significant fatty liver disease (glucagon receptor may specifically help)
You've plateaued on tirzepatide and need something more potent
You're willing to wait for FDA approval (expected 2026–2027)

Bottom Line:

Tirzepatide is the proven choice available today. Retatrutide is the next evolution, showing even greater weight loss in trials, but isn't yet approved. If you need treatment now, tirzepatide is excellent. If you can wait, retatrutide may set a new standard — both are from Eli Lilly, so the transition should be seamless when the time comes.

Frequently Asked Questions

What is the difference between tirzepatide and retatrutide?▼

Tirzepatide is a dual GLP-1/GIP receptor agonist, while retatrutide is a triple GLP-1/GIP/glucagon receptor agonist. Retatrutide adds glucagon receptor activation, which increases energy expenditure and fat burning beyond what tirzepatide achieves.

How much weight can you lose on retatrutide vs tirzepatide?▼

In clinical trials, tirzepatide showed 22.5% mean weight loss (SURMOUNT-1, 72 weeks). Retatrutide showed approximately 28.7% weight loss (TRIUMPH-4 Phase 3). These are from different trials and not directly comparable.

Is retatrutide FDA approved?▼

No, retatrutide is not yet FDA-approved as of 2026. It is in Phase 3 clinical trials (TRIUMPH program) by Eli Lilly. Tirzepatide (Mounjaro/Zepbound) is FDA-approved for T2D and obesity.

What does the glucagon receptor do in retatrutide?▼

Glucagon receptor activation increases energy expenditure, promotes liver fat burning, and enhances thermogenesis. This third mechanism is what differentiates retatrutide from tirzepatide and likely drives the greater weight loss.

Will retatrutide replace tirzepatide?▼

It's too early to say definitively. Both are made by Eli Lilly and may serve different segments — tirzepatide for standard treatment and retatrutide for patients needing maximum weight loss. They'll likely coexist.

What are the side effects of retatrutide compared to tirzepatide?▼

Both share GI side effects (nausea, diarrhea, vomiting). Retatrutide's glucagon component may cause slightly elevated heart rate. Tirzepatide has a more established safety profile with years of post-market data.

🛒 Recommended Products

Products commonly used alongside GLP-1 weight loss therapy

📊 Smart Scale Track weight, BMI, and body composition 🍱 Meal Prep Containers Portion control for calorie management 💪 Protein Powder Maintain muscle mass during weight loss 📏 Measuring Tape Track inches lost beyond just weight

Affiliate links help support MeetPeptide at no extra cost to you.

Related Comparisons & Tools

Explore more weight loss peptide resources

Semaglutide vs Tirzepatide Ozempic vs Mounjaro Dosing Calculator All Comparisons

⚕️ Disclaimer: This comparison is for educational and research reference only. It does not constitute medical advice. Tirzepatide is FDA-approved; retatrutide is investigational and not yet approved. Always consult your healthcare provider. Data cited is from published clinical trials.